再鼎医药(09688)今日盘中大涨5%,引发市场广泛关注。
消息面上,再鼎医药与Novocure合作的3期临床研究PANOVA-3取得阳性主要终点结果。该研究评估了联合方案用于一线治疗不可切除、局部晚期胰腺癌,中位总生存期较对照组有统计学显著改善。
此次研究进展极大增强了肿瘤电场技术应用于胰腺癌适应症的前景。Novocure计划根据研究结果提交上市申请,而再鼎医药亦将在中国申请上市审批。投资者对于该技术管线价值的预期上升,推动公司股价出现大涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.